ORNITHINE ASPARTATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H12N2O2.C4H7NO4
Molecular Weight	265.2637
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

InChIKey=IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

InChI=1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

HIDE SMILES / InChI

Description
Sources: http://www.hmdb.ca/metabolites/HMDB00214
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00129

Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. Ornithine is also a precursor of citrulline and arginine. Arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of arginine in tissues throughout the body. As de novo synthesis of arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to arginine).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
G-protein coupled receptor family C group 6 member A 22 Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628	Agonist 2678		112.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dietary shortage or imbalance 9 Sources: https://www.drugbank.ca/drugs/DB00129	Primary		Approved 8429	L-Ornithine Approved Use Used for nutritional supplementation, also for treating dietary shortage or imbalance.

PubMed

Title	Date	PubMed
[Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome].	2001	11462710
Cancer chemopreventive activities of S-3-1, a synthetic derivative of danshinone.	2001	11355772
Diagnosis of Japanese patients with HHH syndrome by molecular genetic analysis: a common mutation, R179X.	2001	11355015
Possible implications of arginase and diamine oxidase in prostatic carcinoma.	2001	11270424
Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase.	2001 Apr	11297489
Derivatization and chromatographic behavior of the o-phthaldialdehyde amino acid derivatives obtained with various SH-group-containing additives.	2001 Apr 13	11355824
Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance.	2001 Aug	11510941
N(delta)-(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer.	2001 Jan	11170600
Medical and surgical therapy of the cystine stone patient.	2001 Jul	11429493
Abnormal elution behavior of ornitine derivatized with 1-fluoro-2,4-dinitrophenyl-5-leucinamide in advanced Marfey's method.	2001 Jul 6	11471802
Experimental chronic arthritis and granulomatous inflammation induced by bifidobacterium cell walls.	2001 Jul-Aug	11439164
Methohexital affects neutrophil (PMN) dynamic free amino acid pool and immune functions in vitro.	2001 Jun	11412289
Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa.	2001 Jun	11390682
Occupational lead exposure and amino acid profiles and liver function tests in industrial workers.	2001 Jun	11382350
Arginase I expression and activity in human mononuclear cells after injury.	2001 Mar	11224628
Gastrectomized patients are in a state of chronic protein malnutrition analyses of 23 amino acids.	2001 Mar-Apr	11379360
Nitric oxide modulates cardiac performance in the heart of Anguilla anguilla.	2001 May	11316492

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Measurement of Ca2+-dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of human family C G-protein-coupled receptor hGPRC6A/homologous goldfish 5.24 receptor chimeric construct (h6A/5.24) and identification of L-amino acids as agonists. The most active agonists were L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules (only L-Arg, L-Lys, and L-ornithine were able to activate h6A/5.24 at 10 uM concentration).

Name

Type

Language

ORNITHINE ASPARTATE

Common Name

English

L-ORNITHINE, L-ASPARTATE (1:1)

Common Name

English

L-ORNITHINE-L-ASPARTATE (SALT)

Common Name

English

L-ORNITHINE L-ASPARTATE

Common Name

English

ORPARAN

Brand Name

English

Ornithine aspartate [WHO-DD]

Common Name

English

L-ASPARTIC ACID, COMPD. WITH L-ORNITHINE (1:1)

Common Name

English

ORNITHINE, L-, L-ASPARTATE (1:1)

Common Name

English

ORMETA

Brand Name

English

ORNITHINE L-FORM ASPARTATE [MI]

Common Name

English

RUIGAN

Brand Name

English

ASPARTIC ACID COMPD. WITH ORNITHINE

Systematic Name

English

ASPARTIC ACID, L-, COMPD. WITH L-ORNITHINE (1:1)

Common Name

English

ORNITHINE L-FORM ASPARTATE

Common Name

English

HEPAMERZ

Brand Name

English

L-ORNITHINE-L-ASPARTATE

Common Name

English

LOLA

Common Name

English

Classification Tree Code System Code

DSLD

4334 (Number of products:33)